minute read
The U.S. Food and Drug Administration (FDA) approved daraxonrasib (sold as Rasonque), a groundbreaking targeted pill for advanced pancreatic cancer by Revolution Medicines.
Topics: Press Coverage
1665 North Aurora Court
2004
Aurora, CO 80045
720-848-0300
© 2025 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.
